ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Summary

The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).

Eligibility

Inclusion Criteria:

* Age ≥18 years;
* Planned coronary angiogram and/or PCI;
* Willingness to participate and to attend study visits;
* Expected life expectancy ≥6 months.

Exclusion Criteria:

* Cardiogenic or non-cardiogenic shock at the time of the procedure;
* Emergent procedures (e.g. STEMI);
* Iodine-based contrast media received within 2 days;
* Presence of Intra-Aortic Balloon Pump (IABP);
* Cardiac arrest within 24 hours;
* Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
* Renal replacement therapy;
* Severe aortic or mitral disease;
* LVEF \<30%.

Conditions2

Browse More Trials